Compass Therapeutics, Inc. Common Stock

Day range

$0.74 – $0.79

Open

$0.75

Prev close

$0.76

Volume

2.2M

Market cap

$137.05M

Shares out

180.09M

P/E

—

P/S

—

P/B

0.82

P/FCF

—

ROE

-44.2%

ROA

-38.6%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Investor presentationJul 1, 2026

  On July 1, 2026, Compass Therapeutics, Inc. updated its corporate presentation to reflect its most recent corporate updates, including data from the COMPANION-002 clinical study. A copy of the corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

• Bylaw amendmentJun 23, 2026

  On June 22, 2026, the Board of Directors (the "Board") of Compass Therapeutics, Inc. (the "Company") approved the adoption of the Second Amended and Restated Bylaws of the Company, effective as of June 22, 2026 (the "New Bylaws"), which amend and restate the Amended and Restated Bylaws of the Company, dated as of July 17, 2020 (the "Existing Bylaws"), in their entirety. The New Bylaws amended the Existing Bylaws to establish exclusive jurisdiction in the United States District Courts for the District of Delaware and District of Massachusetts for resolving any action asserting a claim arising under Securities Act of 1933, as amended.

• Director appointmentJun 11, 2026

  The stockholders elected the two Class III nominees for director to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. Thomas J. Schuetz, M.D., Ph.D. received 102,984,184 votes for and Richard S. Lindahl, M.B.A. received 103,453,540 votes for.

• Investor presentationApr 27, 2026

  The Company will host a webcast today, Monday, April 27, 2026 at 8:00 a.m. ET, to provide a review of the data. A copy of the presentation to be shown at the webcast on April 27, 2026, is attached as Exhibit 99.2 to this Current Report on Form 8-K.

• Preliminary resultsJan 6, 2026

  The Company disclosed its estimate that cash, cash equivalents and marketable securities were approximately $209 million as of December 31, 2025. This amount is unaudited and preliminary and is subject to the completion of financial closing procedures.

Days to cover

6.3

Short interest

40.36M

Avg volume

6.45M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
  neutralGlobeNewswire Inc.· Oct 24, 2026
• Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
  positiveGlobeNewswire Inc.· Jul 17, 2026
• Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
  positiveGlobeNewswire Inc.· May 21, 2026
• Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
  negativeGlobeNewswire Inc.· Apr 27, 2026
• Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
  neutralGlobeNewswire Inc.· Apr 24, 2026